Dobutamine
From Wikipedia, the free encyclopedia
 |
|
|
Dobutamine
|
|
| Systematic (IUPAC) name | |
| 4-[2-[3-(4-hydroxyphenyl)-1-methyl-propyl] aminoethyl]benzene-1,2-diol | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H23NO3 |
| Mol. mass | 301.38 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 2 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dobutamine is a beta-1 adrenergic agonist. It is a direct-acting agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart, increasing contractibility and cardiac output. Since it does not act on dopamine receptors to induce the release of norepinephrine (an alpha-1 agonist), dobutamine is less prone to induce hypertension than dopamine. Chronotropic, arrhythmogenic, and vasodilative effects are negligible. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, which could be the result of either organic heart disease or cardiac surgical procedures.
Dobutamine, Dopamine, Epinephrine, Fenoldopam, Isoprenaline, Metaraminol, Midodrine, Norepinephrine, Octopamine, Phenylephrine
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
